BMS has announced deucravacitinib: the generic name for its Tyk2 inhibitor (BMS-986165) - 15 long makes it a new rheum labeling record. It's being studied in Psoriatic arthritis, psoriasis, lupus and inflammatory bowel disease. https://t.co/E2x2lelktO